On June 2nd local time, AstraZeneca announced that positive results from the LAURA Phase III trial showed that Teresa (ositinib) showed statistically significant and highly clinically significant improvements in progression free survival (PFS) after chemoradiotherapy (CRT) compared to placebo in unresectable stage III epidermal growth factor receptor (EGFRm) non small cell lung cancer (NSCLC) patients with tumor exon 19 deletion or exon 21 (L858R) mutation.
The results of blind independent central review (BICR) evaluation showed that compared to placebo, Teresa can reduce the risk of disease progression or death by 84%. The median PFS of patients receiving Teresa treatment was 39.1 months, while the median PFS of patients receiving placebo treatment was 5.6 months.
The overall survival (OS) data shows a favorable trend for Teresa, although the data was not mature at the time of this analysis. This trial will continue to evaluate the secondary endpoint OS.